Patrick Daly

DocwireNews

Based on subanalyses of participants with multiple cardiovascular comorbidities in the <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2019422">EAST-AFNET 4</a> trial, researchers suggested a CHA2DS2-VASc score of 4 was an effective indication for early rhythm control (ERC) to reduce adverse cardiovascular outcomes in recently diagnosed patients with atrial fibrillation and risk factors for stroke; however, patients with a lower comorbidity burden may achieve less favorable outcomes.This study, published in Circulation, reviewed outcomes of ERC and usual care (UC) in 2789 patients categorized as either higher (CHA2DS2-VASc score &ge; 4) or lower (CHA2DS2-VASc score &lt; 4) comorbidity burden.<h3>ERC for Atrial Fibrillation Lacks Efficacy in Patients With Lower Comorbidity Burden</h3>Compared with UC, ERC effectively reduces the primary composite outcome of cardiovascular death, hospitalization for worsening heart failure, stroke, and acute coronary syndrome for patients with events in the higher comorbidity burden group (ERC, 127/549 patients; UC, 183/544 patients; hazard ratio [HR], 0.64; 95% CI, 0.51-0.81; P&lt;.001) but not for those with events in the lower comorbidity burden group (ERC, 122/846 patients; UC, 133/850 patients; HR, 0.93; 95% CI, 0.73-1.19; P=.56; interaction, P=.037).Related: <a href="https://www.docwirenews.com/condition-center/atrial-fibrillation/generalizability-of-trial-findings-supporting-early-rhythm-control-in-atrial-fibrillation/">Generalizability of EAST-AFNET 4 Findings</a>Likewise, primary safety outcomes were comparable between UC and ERC in patients with higher comorbidity burden (HR, 0.84; 95% CI, 0.65-1.08; P=.175) but were more frequent among patients with lower comorbidity who received ERC (HR, 1.39; 95% CI, 1.05-1.82; P=.019; interaction, P=.008). The authors did note that rates of life-threatening events or death were similar between the groups.In their full report, the authors summarized that &ldquo;patients with recently diagnosed AF and multiple cardiovascular comorbidities should have rapid, priority access to rhythm control therapy to reduce cardiovascular outcomes.&rdquo;They further suggested that &ldquo;the safety signal identified in these analyses highlights the need to develop safer ways to deliver ERC, especially in patients with few cardiovascular conditions.&rdquo;Find More <a href="https://www.docwirenews.com/atrial-fibrillation/">Expert Interviews and Research on the Atrial Fibrillation Knowledge Hub</a>

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Latest News

Early Rhythm Control Outcomes in Patients With Multiple Comorbidities

Atrial Fibrillation

Based on subanalyses of participants with multiple cardiovascular comorbidities in the EAST-AFNET 4 trial, researchers suggested a CHA2DS2-VASc score of 4 was an effective ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe